1. Introduction
===============

Gastric cancer (GC), as the third leading cause of cancer death in men and the fifth in women, remains one of the major public health problems worldwide \[[@B1-ijms-15-22902]\]. About two-thirds of the cases occur in developing countries and 42% in China alone, while the estimated high-risk areas in developed countries include Eastern Europe, and parts of Central and South America \[[@B2-ijms-15-22902]\]. In recent decades, its incidence rate has declined, and remarkable progress has been achieved in comprehensive treatment strategies of combined therapy. However, the prognosis for patients still remains poor, with 5-year overall survival rates of 30% \[[@B3-ijms-15-22902]\]. The development of gastric cancer is a multi-step, sequential process, which initiates from chronic gastritis, atrophy, intestinal metaplasia, dysplasia, and finally malignant transformation to invasive gastric cancer \[[@B4-ijms-15-22902]\]. Moreover, multiple genetic and epigenetic alterations are implicated in the multi-step process of human stomach carcinogenesis and development \[[@B5-ijms-15-22902]\]. Therefore, discovery of these biomarkers could be helpful in the improvement of early diagnosis, screening of high-risk individuals, as well as patient care \[[@B6-ijms-15-22902],[@B7-ijms-15-22902]\]. In recent years, increased studies have focused on the detection of genetic variants that could play roles in the development, progression and prognoses of gastric cancer \[[@B8-ijms-15-22902]\].

The orphan nuclear receptor (NR5A2), also known as liver receptor homologue-1 (LRH-1) and fetoprotein transcription factor (FTF), belongs to the NR5A or FTZ-F1 subfamily of nuclear receptors. NR5A2 is expressed in developing and adult tissues of endodermal origin, including liver, pancreas, intestine and the ovary \[[@B9-ijms-15-22902],[@B10-ijms-15-22902]\]. Functionally, NR5A2 has been implicated in the regulation of bile acid and cholesterol homeostasis \[[@B9-ijms-15-22902],[@B10-ijms-15-22902]\] and the regulation of inflammatory responses in the liver and gut \[[@B11-ijms-15-22902]\]. Aromatase is an *NR5A2* target gene, which catalyses the conversion of androgens (testosterone and primarily androstenedione) to oestrogens. *NR5A2* may aid breast cancer progression in postmenopausal women by promoting local oestrogen biosynthesis \[[@B12-ijms-15-22902],[@B13-ijms-15-22902],[@B14-ijms-15-22902]\]. The expression of *NR5A2* is also elevated in pancreatic cancer and promotes pancreatic cancer cell growth through stimulation of *cyclin D1*, *cyclin E1 and c-Myc* \[[@B15-ijms-15-22902]\]. A recent genome-wide association study (GWAS) identified rs3790844 and rs3790843, located in the first intron of *NR5A*2 in 1q32.11, as associated with pancreatic cancer susceptibility \[[@B16-ijms-15-22902]\]. In the gastrointestinal tract, *NR5A2* has been shown to participate in intestinal cell renewal \[[@B17-ijms-15-22902]\] and is expressed in the stomach epithelium \[[@B18-ijms-15-22902]\]. Therefore, we conducted this study to examine whether *NR5A2* rs3790844 and rs3790843 polymorphisms are associated with clinical outcomes of gastric cancer. The two SNPs may serve as potential molecular prognostic markers for gastric cancer, which will promote further defined sub-populations at higher risk of the disease. Consequently, these sub-populations may require more rigorous treatment and postoperative follow up.

2. Results
==========

2.1. Associations between Clinicopathological Variables and Overall Survival
----------------------------------------------------------------------------

The patients' characteristics and clinical information are summarized in [Table 1](#ijms-15-22902-t001){ref-type="table"}. In the follow-up period of 119 months, 442 patients died. There were 727 males (77.0%) and 217 females (23.0%), with a median age of 62 years ranging from 28 to 83 years. Clinicopathological characteristics including tumor size, depth of invasion, lymph node metastasis, distant metastasis, Tumor, Node and Metastasis (TNM) stage and Lauren classification were significantly associated with survival time (log-rank *p* \< 0.05). Specifically, patients with tumor size \>5 cm (median survival time (MST), 48 months) had a 42% significantly higher risk of death (HR (hazard ratio) = 1.42, 95% CI (confidence interval) = 1.178--1.716), compared with those with tumor size \<5 cm (MST, 98 months), and the patients with lymph node metastasis or distant metastasis had significantly higher risk of death than those patients without lymph node metastasis or distant metastasis (log-rank *p* \< 0.05). In addition, as the depth of invasion and TNM stage increased, the risk of death for gastric cancer showed a significant increase in a dose-response manner (log-rank *p* \< 0.05).
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###### 

Associations between clinicopathological variables and overall survival.

  Variable                        Patients, *n* = 944   MST (Months)   Log-Rank *p*   HR (95% CI) ^d^
  ------------------------------- --------------------- -------------- -------------- ----------------------
  **Age (years)**                                                                     
  ≤60                             442                   88             0.239          1.000
  \>60                            502                   59                            1.118 (0.927--1.349)
  **Sex**                                                                             
  Male                            727                   70             0.536          1.000
  Female                          217                   63                            1.071 (0.860--1.335)
  **Tumor Size**                                                                      
  ≤5 cm                           581                   98             \<0.001        1.000
  \>5 cm                          363                   48                            1.422 (1.178--1.716)
  **Location**                                                                        
  Non-Cardia                      626                   78             0.253          1.000
  Cardia                          318                   63                            0.891 (0.730--1.088)
  **Histological Types ^a^**                                                          
  Intestinal                      370                   74             0.436          1.000
  Diffuse                         497                   60                            1.069 (0.918--1.244)
  **Differentiation ^a^**                                                             
  Well to Moderate                305                   80             0.518          1.000
  Poorly                          493                   59                            1.165 (0.942--1.443)
  Mucinous/Signet-Ring Cell       69                    62                            1.199 (0.825--1.742)
  **Lauren ^a^**                                                                      
  1                               399                   76             \<0.001        1.000
  2                               541                   50                            1.467 (1.211--1.776)
  **Depth of Invasion ^b^**                                                           
  T1                              182                   84             \<0.001        1.000
  T2                              138                   78                            0.540 (0.408--0.714)
  T3                              8                     70                            0.800 (0.608--1.054)
  T4                              594                   51                            1.008 (0.416--2.442)
  **Lymph Node Metastasis ^c^**                                                       
  N0                              378                   81             \<0.001        1.000
  N1/N2/N3                        566                   43                            1.814 (1.480--2.222)
  **Distant Metastasis**                                                              
  M0                              886                   74             0.004          1.000
  M1                              58                    26                            1.646 (1.165--2.326)
  **TNM Stage**                                                                       
  I                               250                   83             \<0.001        1.000
  II                              203                   88                            1.231 (0.909--1.666)
  III                             458                   41                            1.949 (1.524--2.492)
  IV                              25                    44                            2.046 (1.163--3.600)
  **Chemotherapy**                                                                    
  No                              638                   61             0.684          1.000
  Yes                             306                   69                            1.043 (0.852--1.276)

Mean survival time was presented when the median survival time could not be measured. TNM, Tumor, Node and Metastasis; MST, median survival time; HR, hazard ratio; CI, confidence interval; AJCC, American Joint Commission on Cancer. ^a^: Partial data were not available, and statistics were based on available data; ^b^: Invaded depth of tumor was classified according to the criteria of AJCC 7th; ^c^: Lymph nodes were staged according to tumor node metastasis classification of the 7th edition of AJCC in which the number of lymph nodes with a metastasis of 1--2, 3--6, and ≥7 were classified as N1, N2, and N3, respectively; ^d^: Adjusted by age and sex.

2.2. Association Analyses of NR5A2 rs3790843 and rs3790844 Genotypes with Clinicopathological Features
------------------------------------------------------------------------------------------------------

Among 944 specimens from patients with gastric cancer, *NR5A2* rs3790843 was successfully genotyped in 907 specimens, and *NR5A2* rs3790844 was successfully genotyped in 912 specimens. The frequency of each *NR5A2* rs3790843 genotypes was 45.6% (414 specimens) for the TT variant, 45.2% (410 specimens) for the CT variant, and 9.2% (83 specimens) for the CC variant. [Table 2](#ijms-15-22902-t002){ref-type="table"} indicates that the risk of GC for the CT and CC variants compared with that for the TT variant in *NR5A2* rs3790843 was associated significantly with regional lymph node metastasis (*p* = 0.044) and distant metastasis (*p* = 0.020) but not with age, sex, tumor size or location, histological type, differentiation, depth of invasion, chemotherapy history, American Joint Committee on Cancer staging, or Lauren classification. In reference to *NR5A2* rs3790844, the GG, GA, and AA genotypes were identified in 399 specimens (43.8%), 416 specimens (45.6%), and 97 specimens (10.6%), respectively. Compared with the GG genotype, the GA/AA genotypes were not associated with any clinicopathologic data.
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###### 

Association analyses of *NR5A2* rs3790843 and rs3790844 genotypes with clinicopathological features.

  Variable                                            rs3790843 (*n* = 907)   rs3790844 (*n* = 912)                       
  ------------------------------- ------------------- ----------------------- ----------------------- ------- ----- ----- -------
  **Age (years)**                 ≤60                 192                     237                     0.610   182   249   0.380
  \>60                            222                 256                     217                     264                 
  **Sex**                         Male                321                     375                     0.601   311   391   0.539
  Female                          93                  118                     88                      122                 
  **Location**                    Non-Cardia Cancer   279                     320                     0.432   264   338   0.930
  Cardia Cancer                   135                 173                     135                     175                 
  **Tumor Size**                  ≤5 cm               261                     302                     0.581   243   324   0.486
  \>5 cm                          153                 191                     156                     189                 
  **Lymph Node Metastasis ^a^**   N0                  180                     182                     0.044   168   197   0.257
  N1/N2/N3                        234                 311                     231                     316                 
  **Distant Metastasis**          M0                  398                     456                     0.020   382   478   0.098
  M1                              16                  37                      9                       35                  
  **Histological Types ^b^**      Intestinal          168                     187                     0.273   156   205   0.541
  Diffuse                         207                 270                     206                     270                 
  **Differentiation ^b^**         Well to Moderate    137                     155                     0.556   127   170   0.687
  Poorly                          208                 267                     205                     270                 
  Mucinous/Signet-Ring Cell       30                  35                      30                      35                  
  **Lauren ^b^**                  1                   182                     199                     0.253   169   218   0.450
  2                               229                 293                     227                     294                 
  **Chemotherapy**                No                  275                     333                     0.721   266   348   0.709
  Yes                             139                 160                     133                     165                 
  **Depth of Invasion ^c^**       T1                  86                      93                      0.854   76    101   0.929
  T2                              60                  69                      59                      71                  
  T3                              3                   3                       2                       4                   
  T4                              257                 320                     254                     326                 
  **TNM Stage**                   I                   120                     118                     0.369   111   128   0.533
  II                              83                  111                     78                      119                 
  III                             198                 248                     198                     250                 
  IV                              10                  13                      9                       13                  

HR, hazard ratio; CI, confidence interval; AJCC, American Joint Commission on Cancer; TNM, Tumor, Node and Metastasis. ^a^: Lymph nodes were staged according to tumor node metastasis classification of the 7th edition of AJCC in which the number of lymph nodes with a metastasis of 1--2, 3--6, and ≥7 were classified as N1, N2, and N3, respectively; ^b^: Partial data were not available, and statistics were based on available data; ^c^: Invaded depth of tumor was classified according to the criteria of AJCC 7th.

The distribution of genotypes in the population was consistent with Hardy--Weinberg equilibrium (*p* = 0.20 for rs3790843 SNP, *p* = 0.46 for rs3790844 SNP), while strong linkage disequilibrium (LD) exists between alleles of the two loci with the following *R*~2~ values: rs3790843/rs3790844 = 0.798. Haplotype analyses were performed for all patients using the SHEsis software ([http://analysis. bio-x.cn](http://analysis. bio-x.cn)), and the six possible haplotype frequencies of the two SNPs are shown in [Table 3](#ijms-15-22902-t003){ref-type="table"}. According to the results, the TTGG and CTGA haplotypes are the most common and represent 41.5% and 40.8%, respectively, in all groups. After haplotype analyses, however, no significant differences in these haplotype frequencies were found in any group.
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###### 

Haplotype analyses of *NR5A2* rs3790843 and rs3790844 genotypes.

  Haplotype   Frequencies   Patients/Deaths   HR (95% CI) ^a^
  ----------- ------------- ----------------- -------------------
  TTGG        0.415         379/184           1.00
  CTGA        0.408         373/170           0.90 (0.73--1.10)
  CCAA        0.079         72/30             0.79 (0.54--1.17)
  TTGA        0.036         33//11            0.54 (0.30--1.00)
  CTAA        0.024         22//6             0.47 (0.21--1.07)
  CTGG        0.015         14//10            1.55 (0.81--2.94)

^a^: Adjusted by age and sex.

2.3. Associations of NR5A2 rs3790843 and rs3790844 with Clinical Outcomes of OS
-------------------------------------------------------------------------------

The Kaplan-Meier survival analysis and Cox proportional hazard models were used to assess the prognostic effect of *NR5A2* rs3790843 and rs3790844 on GC patients in different genetic models ([Table 4](#ijms-15-22902-t004){ref-type="table"}). We found rs3790844 polymorphism was associated with the OS of GC patients in the dominant model (GG *vs.* GA/AA, log-rank *p* = 0.045, [Figure 1](#ijms-15-22902-f001){ref-type="fig"}). Patients with the GA or AA genotype (MST 88 months) had a 17.7% lower risk of death than that of patients with the GG genotype (MST 52 months) (HR = 0.823, 95% CI = 0.679--0.997), suggesting a potential protective role of the variant A allele. No significant associations were observed between the rs3790843 genotypes and OS of GC patients in any genetic models. We further evaluated the associations by stratified analysis of variants of clinicopathological features ([Table 5](#ijms-15-22902-t005){ref-type="table"}). In the dominant model, *NR5A2* rs3790844 polymorphism was associated with significantly lower risk of death in the groups of patients with lymph node metastasis, no distant metastasis, diffuse type and no chemotherapy history (log-rank *p* \< 0.05). Additionally, both *NR5A2* rs3790843 and rs3790844 polymorphism were associated with significantly better prognosis among the female patients group and tumor size \>5 cm group in a dominant model. Cox stepwise regression analysis was conducted to evaluate the independent effect of clinicopathological variables, rs3790843 and rs3790844 SNP on the OS of the patients with GC. As shown in [Table 6](#ijms-15-22902-t006){ref-type="table"}, two variables (lymph node metastasis and *NR5A2* rs3790844) were included in the regression model by stepwise selection of the covariant variables and rs3790844 SNP was shown to be an independent protective factor for GC with a 21.6% decreased risk (HR = 0.784, 95% CI = 0.646--0.951, *p* = 0.014).
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###### 

Associations of *NR5A2* rs3790843 and rs3790844 with clinical outcomes of overall survival.

  Genetic Model      Genotypes   Patients   Deaths   MST (Months)           Log-Rank *p*   HR (95%CI) ^a^
  ------------------ ----------- ---------- -------- ---------------------- -------------- ----------------
  **rs3790843**                                                                            
  Codominant Model   TT          414        196      59                     0.668          1.000
  CT                 410         187        70       0.934 (0.765--1.142)                  
  CC                 83          36         88       0.872 (0.611--1.244)                  
  Dominant Model     TT          414        196      59                     0.415          1.000
  CT or CC           493         223        70       0.924 (0.762--1.119)                  
  Recessive Model    TT or CT    824        383      70                     0.551          1.000
  CC                 83          36         88       0.902 (0.641--1.269)                  
  **rs3790844**                                                                            
  Codominant Model   GG          399        197      52                     0.075          1.000
  GA                 416         186        78       0.853 (0.698--1.043)                  
  AA                 97          37         98       0.699 (0.492--0.993)                  
  Dominant Model     GG          399        197      52                     0.045          1.000
  GA or AA           513         223        88       0.823 (0.679--0.997)                  
  Recessive Model    GG or GA    815        383      65                     0.103          1.000
  AA                 97          37         98       0.757 (0.540--1.061)                  

MST, median survival time; HR, hazard ratio; CI, confidence interval. Mean survival time was presented when the median survival time could not be measured. ^a^: Adjusted by age and sex.

3. Discussion
=============

In the present study, we investigated the effects of two SNPs (rs3790843 and rs3790844) of the *NR5A2* gene on the progression and survival of GC in Chinese populations. We found that *NR5A2* rs3790843 polymorphism was significantly associated with the risk of GC when compared with regional lymph node metastasis and distant metastasis. Our results also indicated that rs3790844 polymorphism was associated with the increased OS of GC patients in the dominant model, suggesting a potential protective role of the variant A allele. No significant associations were observed between the rs3790843 genotypes and OS of GC patients in any genetic models. Additionally, in the stratified analysis, *NR5A2* rs3790844 polymorphism was associated with significantly lower risk of death in the groups of female, tumor size \>5 cm, lymph node metastasis, no distant metastasis, diffuse type and no chemotherapy history in the dominant model. Similar results were found among the female patients group and tumor size \>5 cm group for the *NR5A2* rs3790843 polymorphism in a dominant model.

![Overall survival curve in relation to *NR5A2* rs3790844 polymorphism in patients with gastric cancer in dominant model.](ijms-15-22902-g001){#ijms-15-22902-f001}

Nuclear receptor 5 subtype A2 (NR5A2), also known as Liver receptor homolog-1 (LRH-1), is a member of the orphan family of nuclear receptors that participates in a wide range of developmental processes \[[@B9-ijms-15-22902],[@B10-ijms-15-22902]\]. Functionally, NR5A2 has been implicated in the regulation of bile acid and cholesterol homeostasis, and is expressed in developing and adult tissues of endodermal origin, including liver, pancreas, intestine and the ovary \[[@B9-ijms-15-22902],[@B10-ijms-15-22902]\]. *NR5A2* was first isolated as a transcriptional activator of the alpha-fetoprotein (*AFP*) gene, which encodes a factor that plays a crucial rolein hepatic specification \[[@B19-ijms-15-22902]\]. Further, *NR5A2* expression is elevated in pancreatic cancer andpromotes pancreatic cancer cell growth through stimulation of *cyclin D1*, *cyclin E1 and c-Myc* \[[@B15-ijms-15-22902]\], while genome-wide association studies implicate mutations in the *NR5A2* gene in pancreatic ductal adenocarcinoma \[[@B16-ijms-15-22902]\]. In the gastrointestinal tract, *NR5A2* has been shown to participate in intestinal cell renewal \[[@B17-ijms-15-22902]\] and is expressed in the stomach epithelium \[[@B18-ijms-15-22902]\]. However, it seemed no study focused on the association between *NR5A2* and the progression and prognoses of gastric cancer. Thus, this study was conducted, and it indicates that the *NR5A2* polymorphism is significantly associated with the development and overall survival of gastric cancer.

In the gastrointestinal tract, *NR5A2* regulates proliferation through at least two different mechanisms: direct activation of the *cyclin E1* promoter and, in cooperation with *β-catenin*, induction of *cyclin D1* and *c-Myc* transcription \[[@B20-ijms-15-22902]\]. A previous study showed that *NR5A2*, which interacts with *β-catenin*, induces cell proliferation through the concomitant induction of *cyclin D1* and *E1*, which are downstream *NR5A2* effectors whose induction may account for the diminished threshold for G/S transition \[[@B20-ijms-15-22902]\]. Whereas *β-catenin* coactivates *NR5A2* on the *cyclin E1* promoter, *NR5A2* acts as a potent tissue-restricted coactivator of *β-catenin* on the *cyclin D1* promoter.

ijms-15-22902-t005_Table 5

###### 

Stratified analysis of rs3790843 and rs3790844 polymorphism among GC patients.

                                  rs3790843   rs3790844                                                                              
  ------------------------------- ----------- ----------- ----------------------- ------- --------- --------- ---------------------- -------
  **Age (years)**                                                                                                                    
  ≤60                             88/192      108/237     0.977 (0.737--1.294)    0.869   90/182    107/249   0.806 (0.609--1.067)   0.132
  \>60                            108/222     115/256     0.873 (0.672--1.136)    0.313   107/217   116/264   0.837 (0.644--1.089)   0.185
  **Sex**                                                                                                                            
  Male                            144/321     175/375     1.044 (0.838--1.302)    0.700   149/311   172/391   0.877 (0.705--1.093)   0.243
  Female                          52/93       48/118      0.619 (0.417--0.916)    0.017   48/88     51/122    0.660 (0.445--0.981)   0.040
  **Location**                                                                                                                       
  Non--CardiaCancer               133/279     148/320     0.948 (0.750--1.198)    0.652   133/264   148/338   0.810 (0.641--1.024)   0.077
  CardiaCancer                    63/135      75/173      0.861 (0.615--1.204)    0.381   64/135    75/175    0.840 (0.601--1.174)   0.308
  **Tumor Size**                                                                                                                     
  ≤5 cm                           108/261     127/302     1.044 (0.807--1.349)    0.745   106/243   132/324   0.927 (0.718--1.197)   0.559
  \>5 cm                          88/153      96/191      0.747 (0.558--0.999)    0.049   91/156    91/189    0.693 (0.517--0.928)   0.014
  **Lymph Node Metastasis ^a^**                                                                                                      
  N0                              64/180      60/182      0.947 (0.666--1.347)    0.763   63/168    63/197    0.865 (0.610--1.226)   0.414
  N1/N2/N3                        132/234     163/311     0.829 (0.659--1.043)    0.109   134/231   160/316   0.744 (0.591--0.937)   0.012
  **Distant Metastasis**                                                                                                             
  M0                              188/398     200/456     0.886 (0.726--1.081)    0.232   188/382   202/478   0.793 (0.650--0.968)   0.022
  M1                              8/16        23/37       1.340 (0.599--2.998)    0.476   7/9       21/35     1.189 (0.544--2.599)   0.664
  **Histological Types ^b^**                                                                                                         
  Intestinal                      71/168      80/187      1.041 (0.756--1.434)    0.805   69/156    84/205    0.952 (0.692--1.309)   0.762
  Diffuse                         108/207     127/270     0.826 (0.639--1.068)    0.145   111/206   123/270   0.735 (0.568--0.950)   0.019
  **Differentiation ^b^**                                                                                                            
  Well to Moderate                57/137      67/155      1.099 (0.772--1.565)    0.601   56/127    69/170    0.962 (0.676--1.368)   0.828
  Poorly                          104/208     126/267     0.882 (0.680--1.144)    0.344   105/205   125/270   0.822 (0.634--1.067)   0.140
  Others ^c^                      18/30       14/35       0.522 (0.259--1.056)    0.07    19/30     13/35     0.397 (0.195--0.808)   0.011
  **Lauren ^b^**                                                                                                                     
  1                               69/182      78/199      1.049 (0.759--1.451)    0.771   69/169    80/218    0.899 (0.652--1.241)   0.655
  2                               125/229     144/293     0.824 (0.648--1.047)    0.113   126/227   142/294   0.763 (0.600--0.970)   0.027
  **Chemotherapy**                                                                                                                   
  No                              132/275     151/333     0.908 (0.719--1.147)    0.416   136/266   149/348   0.767 (0.608--0.968)   0.025
  Yes                             64/139      72/160      0.957 (0.683--1.340)    0.799   61/133    74/165    0.953 (0.679--1.338)   0.783
  **Depth of Invasion ^d^**                                                                                                          
  T1                              25/86       34/93       1.297 (0.774--2.173)    0.324   24/76     33/101    1.051 (0.621--1.779)   0.852
  T2                              31/60       24/69       0.669 (0.393--1.141)    0.140   31/59     25/71     0.648 (0.382--1.099)   0.107
  T3                              1/3         2/3         1.405 (0.125--15.838)   0.782   1/2       2/4       0.809 (0.071--9.157)   0.864
  T4                              134/257     159/320     0.880 (0.699--1.108)    0.276   135/254   157/326   0.809 (0.642--1.019)   0.072
  **TNM Stage**                                                                                                                      
  I                               40/120      39/118      0.992 (0.638--1.542)    0.972   40/111    40/128    0.862 (0.556--1.336)   0.506
  II                              38/83       38/111      0.743 (0.474--1.166)    0.196   37/78     41/119    0.711 (0.456--1.109)   0.132
  III                             111/198     135/248     0.861 (0.670--1.108)    0.245   113/198   132/250   0.800 (0.622--1.029)   0.082
  IV                              4/10        8/13        1.855 (0.557--6.171)    0.314   4/9       7/13      1.257 (0.368--4.302)   0.715

HR, hazard ratio; CI, confidence interval; AJCC, American Joint Commission on Cancer; TNM, Tumor, Node and Metastasis. ^a^: Lymph nodes were staged according to tumor node metastasis classification of the 7th edition of AJCC in which the number of lymph nodes with a metastasis of 1--2, 3--6, and ≥7 were classified as N1, N2, and N3, respectively; ^b^: Partial data were not available, and statistics were based on available data; ^c^: Others: mucinous carcinoma and Signet-ring cell carcinoma; ^d^: Invaded depth of tumor was classified according to the criteria of AJCC 7th; ^e^: Adjusted by age and sex.
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Stepwise Cox regression analysis on the survival of GC.

  Variables                    β        SE      HR ^b^   95% CI           *p* Value
  ---------------------------- -------- ------- -------- ---------------- -----------
  **Age ^a^**                  0.067    0.100   1.070    (0.878--1.302)   0.503
  **Sex**                      0.04     0.118   1.041    (0.825--1.313)   0.743
  **Lymph Node Metastasis**    0.567    0.112   1.763    (1.414--2.198)   \<0.001
  rs3790844 (GG *vs.* GA/AA)   −0.243   0.099   0.784    (0.646--0.951)   0.014
  rs3790843 (TT *vs.* CT/CC)   −0.152   0.101   0.859    (0.705--1.046)   0.131

β, regression coefficient; SE, standard error; HR, hazard ratio; CI, confidence interval. ^a^: Age was included as a continuous variable in the Cox stepwise regression analysis; ^b^: Adjusted by age and sex.

Tumor growth is the result of uncontrolled cell proliferation or a defective cell death program. For the proliferation of cells, the phosphorylation of pRb by *cyclin--CDK* complexes to release the transcription factor E2F is an essential step. The *cyclin D1*, *cyclin E* and *c-Myc* are important parts of expression peaks at the G1--S transition, and then decreases as cells proceed through the S phase \[[@B21-ijms-15-22902],[@B22-ijms-15-22902],[@B23-ijms-15-22902]\]. The G1--S transition is the major regulation point of the cell cycle, and during the G1--S transition, alterations in cell cycle regulators lead to the deregulation of the cell cycle, which can cause unbridled cell division, contributing to cancer development. Previously, overexpression of *cyclin E* was demonstrated in many tumors and correlated with prognosis \[[@B24-ijms-15-22902],[@B25-ijms-15-22902],[@B26-ijms-15-22902],[@B27-ijms-15-22902]\] including gastric cancer \[[@B28-ijms-15-22902]\]. Wang *et al.* \[[@B29-ijms-15-22902]\] found that the mRNA expression of NR5A2 was significantly upregulated in gastric cancer, as compared with self-paired normal control. In addition, overexpression of NR5A2 was shown to promote the proliferation of gastric adenocarcinoma SGC-7901 cells via induction of *cyclin E1*, which may lead to the tumorigenesis of gastric cancer \[[@B29-ijms-15-22902]\]. Botrugno *et al.* \[[@B20-ijms-15-22902]\] found that *cyclin E* was a direct *NR5A2* target gene, which could partly explain the mechanism of *NR5A2* polymorphism in the progression and prognoses of gastric cancer. On the other hand, *β-catenin* has been proposed to act as a docking protein that assembles both general and specific factors required for the activation of target genes. Botrugno *et al.* also found that *NR5A2* could act as a coactivator for *β-Catenin/Tcf4* to drive the expression of *cyclin D1* and other *β-catenin/Tcf* target genes, such as *c-Myc* \[[@B30-ijms-15-22902],[@B31-ijms-15-22902],[@B32-ijms-15-22902]\]. As reported, *cyclin D1* is a proto-oncogene that belongs to the family of G1 cyclins, and plays an important role in cell cycle G1 to S transition by binding its partners cyclin dependent kinase 4 and 6 to phosphorylate and inactivate the Rb protein \[[@B33-ijms-15-22902]\]. In addition, *cyclin D1* over-expression is usually an early event in carcinogenesis and a prognostic indicator associated with poor survival in cancers \[[@B34-ijms-15-22902]\]. Given above-mentioned evidences, *NR5A2* polymorphism could also affect the carcinogenesis and prognoses of cancer through acting as a coactivator for *β-catenin* on the *cyclin D1* promoter.

Interestingly, in the stratified analyses by sex, our results indicated that both the *NR5A2* rs3790843 and rs3790844 polymorphisms were associated with significantly better prognosis in the female patient group. *NR5A2* is a direct estrogen receptor α (ERα) target gene \[[@B35-ijms-15-22902],[@B36-ijms-15-22902]\], its expression correlates with ERα in breast tumours \[[@B37-ijms-15-22902]\] and it promotes breast cancer proliferation and invasion \[[@B38-ijms-15-22902]\]. Previous study showed that *NR5A2* is an important regulator of ERα target genes and it shares many binding sites with ERα. Importantly, at shared sites, *NR5A2* promotes ERα recruitment and *vice versa*, ERα stimulates *NR5A2* recruitment \[[@B39-ijms-15-22902]\]. As a result, in the female patients with more ERα, more *NR5A2* polymorphisms, which act as a protective factor, contribute to a better prognosis.

Taken together, the presented findings of the potential involvement of the *NR5A2* gene in anti-tumorigenesis prompts us to further characterize its structure, biological function and interaction with other partners by *in vitro* or *in vivo* studies. However, some limitations of the present study should be addressed. First, Helicobacter pylorus, a known crucial factor in gastric carcinogenesis, was not considered due to the lack of related follow-up information. Second, only two SNPs in *NR5A*2 are evaluated, and it is possible that some other important SNPs are neglected or the observed associations may be due to other polymorphisms in linkage disequilibrium with the rs3790843 and rs3790844 polymorphisms. Finally, for validation of the genotype--phenotype relationship, further investigation is underway to clarify the association between rs3790843 and rs3790844 polymorphisms and expression levels of NR5A2 protein in gastric cancer tissues, and will be reported separately.

4. Experimental Section
=======================

4.1. Study Subjects
-------------------

A retrospective cohort of 944 patients with gastric cancer who underwent a surgical resection at the Yixing People's Hospital (Yixing, Jiangsu Province, China) between 1999 and 2006, who had a median follow-up of 35 months (range, 0--119 months) were recruited for this study \[[@B40-ijms-15-22902]\]. The demographic features and clinicopathologic data were summarized in [Table 1](#ijms-15-22902-t001){ref-type="table"}. All patients were diagnosed with gastric carcinoma histopathologically. None had received neoadjuvant radiochemotherapy or postoperative radiotherapy, and some had received adjuvant chemotherapy. Formalin-fixed and paraffin-embedded blocks of these patients were collected from the department of pathology of this hospital. The samples used for genotyping were reviewed and classified by two independent pathologists. Death dates were confirmed via review of death certificates of inpatient and outpatient records or obtained from patients' families through follow-up telephone calls. The study protocol was approved by the Institutional Review Board of Nanjing Medical University (Nanjing, China), and all patients provided written informed consent on the use of paraffin specimens for gene polymorphism analyses.

4.2. Genotyping
---------------

Genomic DNA was extracted from tumor specimens using proteinase K digestion, followed by isopropanol extraction and ethanol precipitation. The *NR5A2* (rs3790844 and rs3790843) SNPs were examined by multiplex snapshot technology using an ABI fluorescence-based assay allelic discrimination method (Applied Biosystems, Foster City, CA, USA), which has been described indetail in a previous study \[[@B41-ijms-15-22902]\]. The primers were designed to anneal immediately adjacent to the nucleotideat the mutation site: rs3790844: forward, 5\'-TTCCGTGTGGAAACACAGGTCA-3\'; reverse, 5\'-TCGACTGGAGCCCAAGATCA-3\'; rs3790843: forward, 5\'-TCTTTGCCCCGATGAGTTCG-3\'; reverse, 5\'-TCCCAGATGCTCTGGTGCAG-3\'. The primers for extension were as follows: rs3790844, 5\'-TTTTTTTTTTTTT...TTTTTTTTTTTTTTTTTGGAAACACAGGTCACTAAAACTGG-3\'; and rs3790843, 5\'-TCTGGTGCAGCCGAAGTAG-3\'. The snapshot products were analyzed by using an ABI 3130 genetic analyzer (Applied Biosystems) and the genotypes were determined by GeneMapper Analysis Software version 4 (Applied Biosystems). Genotype analysis was performed by two investigators blinded to the survival end points. Genotyping was validated by sequencing a randomly selected 10% of samples, and the results were 100% concordant. However, 37 cases of rs3790843 and 32 cases of rs3790844 failed in genotyping because of poor DNA quality, which were excluded in further analysis. Finally, 907 cases of rs3790843 and 912 cases of rs3790844 were included in the analysis.

4.3. Statistical Methods
------------------------

The associations of each genotype or combinations of genotypes with clinicopathologic features were compared using the Pearson chi-square test for categorical variables and the Student's *t*-test for continuous data. Associations of genetic variants and clinicopathological features with the overall survival (OS) were estimated using Kaplan-Meier method and comparisons between different groups of patients were performed with the log-rank test. Univariate or multivariate Cox proportional hazard models was used to estimate the adjusted HR and their 95% CI. Moreover, Cox stepwise regression analysis was conducted to assess the independent impacts of SNP or clinicopathological features on the overall survival after adjusting for other covariates, with a significance level of *p* \< 0.05 for entering and *p* \> 0.10 for removing the respective explanatory variables. All tests were two-sided and *p* \< 0.05 was considered statistically significant. All the statistical analyses were carried out using SPSS version 16.0 for Windows (SPSS Inc., Chicago, IL, USA).

5. Conclusions
==============

In conclusion, our results represent the first demonstration that *NR5A2* rs3790844 polymorphism was associated with the increased OS of GC patients in the dominant model, and similar results were found among the female patients group and tumor size \>5 cm group for the *NR5A2* rs3790843 polymorphism, suggesting that the mutant alleles may serve as suitable markers for predicting the survival of gastric cancer patients, especially in a Chinese population. Large population-based prospective studies with ethnically diverse populations are warranted to verify these findings.
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